Brace yourselves for the unveiling of Madrigal Pharmaceuticals's (NASDAQ: MDGL) third quarter financial results on Thursday 31st October 2024. This eagerly awaited announcement will take place before market open.
It is anticipated by financial experts on Wall Street that the concern is set to announce an estimated $6.95 loss per share for the quarter. Additionally, the firm is expected to disclose a total revenue of $33.16 million for this period.
Analysts on Wall Street have shared their predictions regarding the annual performance of the company, estimating a total revenue of $105.09 million. Additionally, they are expecting the company to achieve per share loss of $27.56 for the fiscal year.
Additionally, The company will host a conference call with investors and analysts on 31st October 2024 at 08:00 AM eastern time to review the Q3 2024 financial results.
The previous trading day saw Madrigal Pharmaceuticals (MDGL) shares trading between $214.20 and $218.43, besides a volume of 215.50 thousand shares. The stock closed Tuesday's regular trading session at $217.79, demonstrating 0.36 percent increase.
